April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Four Years Follow-up of Intravitreal Bevacizumab Therapy in the Treatment of Retinopathy of Prematurity, India-Mexico Collaborative Group Experience
Author Affiliations & Notes
  • Axel Orozco-Hernandez
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • Alay Banker
    Banke
  • Deepa Banker
    Banke
  • Hugo Quiroz-Mercado
    Ophthalmology, Denver Health Medical Center, Denver, Colorado
  • Rohan Chauhan
    Banke
  • Robison V. Chan
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Jose Luis Guerrero-Naranjo
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • Gerardo Garcia-Aguirre
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • Maria Ana Martinez-Castellanos
    Retina, Asoc Para Evitar la Ceguera en Mexico, Mexico City, Mexico
  • Footnotes
    Commercial Relationships  Axel Orozco-Hernandez, None; Alay Banker, None; Deepa Banker, None; Hugo Quiroz-Mercado, None; Rohan Chauhan, None; Robison V. Chan, None; Jose Luis Guerrero-Naranjo, None; Gerardo Garcia-Aguirre, None; Maria Ana Martinez-Castellanos, None
  • Footnotes
    Support  St. Giles Foundation and from a departmental grant from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3161. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Axel Orozco-Hernandez, Alay Banker, Deepa Banker, Hugo Quiroz-Mercado, Rohan Chauhan, Robison V. Chan, Jose Luis Guerrero-Naranjo, Gerardo Garcia-Aguirre, Maria Ana Martinez-Castellanos; Four Years Follow-up of Intravitreal Bevacizumab Therapy in the Treatment of Retinopathy of Prematurity, India-Mexico Collaborative Group Experience. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3161.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The aim of the present study is to report our findings after four years follow up of premature patients from two different countries who were treated with intravitreal bevacizumab (IB) for stage 3, threshold and prethreshold retinopathy of prematurity (ROP).

Methods: : Prospective, multicenter study of 39 eyes with ROP, treated with IB with or without laser. Anatomical results (clinical regression), functional evaluation (electroretinogram [ERG], visual evoked potential [VEP]), and neurodevelopmental analysis (Developmental quotient [DQ]) were performed at 4 years follow-up.

Results: : All eyes showed regression of pathological neovascularization and normal vascular growth was observed. At four years follow up, there was normal retinal function (normal ERG and VEP), and no neurodevelopment abnormalities were observed (normal DQ) in all patients. None of the eyes showed any progression of disease or required any further intervention.

Conclusions: : This 4 year follow up study demonstrates that intravitreal bevacizumab is effective for treatment requiring ROP. No ocular or systemic adverse events were seen in this small series.

Clinical Trial: : http://www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×